Report: Monoclonal antibodies set to drive drug-delivery growth

Monoclonal antibodies are designed to seek out and destroy particular cancer cells, no matter where they're found in the body. According to the market research firm Kalorama Information, a new group of monoclonal antibodies will come on the market in the coming years, driving growth in drug delivery systems, reports.

"Monoclonal antibodies represent one of the largest classes of biotechnological drugs being developed. Several products are currently on the market and many more are expected within the next few years," said Bruce Carlson, publisher of Kalorama Information. "While you won't see the double digit growth that you saw in past years in this area, monoclonal antibodies remain an important part of this multibillion dollar market."

The publication names Roche as "the clear leader in the market," since it involved in the marketing and distribution of the top five: Avastin, Herceptin, Lucentis, Rituxan and Xolair. Abbott, Pfizer and Novartis are all companies with monoclonal products in development, the publication reports.

-

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.